Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. H.W. (Hans) Nijman

Publicaties

APOLLO: neo-adjuvant pembrolizumab for primary vulvar squamous cell carcinoma-a multicenter, single-arm, phase II, clinical proof-of-concept study

B cells critical for outcome in high grade serous ovarian carcinoma

Correction to: Prediction of recurrence risk in endometrial cancer with multimodal deep learning (Nature Medicine, (2024), 10.1038/s41591-024-02993-w)

Diagnostic accuracy of MRI, CT, and [18F]FDG-PET-CT in detecting lymph node metastases in clinically early-stage cervical cancer — a nationwide Dutch cohort study

Genomic instability as a driver and suppressor of anti-tumor immunity

ImmunoPET provides a novel way to visualize the CD103+ tissue-resident memory T cell to predict the response of immune checkpoint inhibitors.

Neoadjuvant immune checkpoint blockade in women with mismatch repair deficient endometrial cancer: a phase I study

Prediction of recurrence risk in endometrial cancer with multimodal deep learning

Prognostic impact and causality of age on oncological outcomes in women with endometrial cancer: a multimethod analysis of the randomised PORTEC-1, PORTEC-2, and PORTEC-3 trials

RB Loss in p53 Abnormal Endometrial Carcinoma: Histological and Clinicopathological Correlates

Lees meer

Pers/media

Ziekenhuiskoepel ziet uitwerking concentratieplannen kankerzorg niet zitten

Kankerzorg straks in minder ziekenhuizen: ‘Niet alle zorg kan meer om de hoek'

‘Niemand kan achteroverleunen’

UMCG ontvangt subsidie voor onderzoek naar immuuntherapie bij baarmoederkanker

Hoogleraar UMCG maakt plan kankerzorg voor Zorginstituut Nederland

Oncoloog Hans Nijman is kwartiermaker netwerk- en expertzorg kanker

„Werk aan de winkel met kankerpreventie”

Subsidie voor minder belastende behandeling schaamlipkanker

Onderzoek naar minder belastende behandeling schaamlipkanker

Subsidie voor minder belastende behandeling schaamlipkanker

Lees meer